ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Dec 2nd, 2020 - Objective: Long-term life experiences, such as education, occupational attainment, leisure activities, and bilingualism, have been considered proxies of cognitive reserve (CR). In neurodegenerative disease, CR is considered as a modulator of a mor...

Dec 1st, 2020 - To identify a novel physiologic marker of bulbar motor involvement in amyotrophic lateral sclerosis (ALS) based on jaw muscle synergies. Muscle synergies were extracted from the surface electromyographic recordings of five jaw muscles during speec...

Nov 30th, 2020 - The aim of this study was to explore the upper motor neurons (UMN) and lower motor neurons (LMN) degeneration in amyotrophic lateral sclerosis (ALS) from the perspective of the clinical neurological examination and MRI-electromyography manifold de...

Nov 27th, 2020 - Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease preferentially affecting motoneurones. Transgenic mouse models have been used to investigate the role of abnormal motoneurone excitability in this disease. Whilst an increased exci...

Nov 26th, 2020 - To identify potential biomarkers of preclinical and clinical progression in chromosome 9 open reading frame 72 gene (C9orf72)-associated disease by assessing the expression levels of plasma microRNAs (miRNAs) in C9orf72 patients and presymptomatic...

Nov 24th, 2019 - Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that Exservan™ (riluzole) Oral Film received early-act...

Jan 8th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

Dec 31st, 2015 - In 2013, MDA launched the U. S.

Sep 14th, 2011 - The evidence base for the diagnosis and management of amyotrophic lateral sclerosis (ALS) is weak. To provide evidence-based or expert recommendations for the diagnosis and management of ALS based on a literature search and the consensus of an exp...

Oct 13th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

Dec 2nd, 2020 - Objective: Long-term life experiences, such as education, occupational attainment, leisure activities, and bilingualism, have been considered proxies of cognitive reserve (CR). In neurodegenerative disease, CR is considered as a modulator of a mor...

Dec 1st, 2020 - To identify a novel physiologic marker of bulbar motor involvement in amyotrophic lateral sclerosis (ALS) based on jaw muscle synergies. Muscle synergies were extracted from the surface electromyographic recordings of five jaw muscles during speec...

Nov 30th, 2020 - The aim of this study was to explore the upper motor neurons (UMN) and lower motor neurons (LMN) degeneration in amyotrophic lateral sclerosis (ALS) from the perspective of the clinical neurological examination and MRI-electromyography manifold de...

Nov 27th, 2020 - Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease preferentially affecting motoneurones. Transgenic mouse models have been used to investigate the role of abnormal motoneurone excitability in this disease. Whilst an increased exci...

Nov 26th, 2020 - To identify potential biomarkers of preclinical and clinical progression in chromosome 9 open reading frame 72 gene (C9orf72)-associated disease by assessing the expression levels of plasma microRNAs (miRNAs) in C9orf72 patients and presymptomatic...

Oct 14th, 2020 - NEW YORK (Reuters Health) - Amyotrophic lateral sclerosis (ALS) patients prescribed edaravone are hospitalized more frequently, a new surveillance study in U.S. military veterans shows. Patients on edaravone had significantly higher rates of all-c...

Oct 14th, 2020 - NEW YORK (Reuters Health) - Amyotrophic lateral sclerosis (ALS) patients prescribed edaravone are hospitalized more frequently, a new surveillance study in U.S. military veterans shows. Patients on edaravone had significantly higher rates of all-c...

Sep 2nd, 2020 - Treatment with a fixed-dose combination of sodium phenylbutyrate and taurursodiol (AMX0035, Amylyx Pharmaceuticals) slows the rate of decline in physical function in patients with amyotrophic lateral sclerosis (ALS), according to results of the ph...

Sep 2nd, 2020 - Treatment with a fixed-dose combination of sodium phenylbutyrate and taurursodiol (AMX0035, Amylyx Pharmaceuticals) slows the rate of decline in physical function in patients with amyotrophic lateral sclerosis (ALS), according to results of the ph...

Jul 8th, 2020 - Two early studies are raising hopes that some genetic forms of amyotrophic lateral sclerosis (ALS) can be treated. Both studies investigated potential benefits of suppressing the toxic activity in cells of a mutant gene (SOD1) that encodes superox...